Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
In the FINEARTS‑HF trial, cardiovascular deaths comprised half of fatalities in HF with EF ≥40%, with sudden death accounting for the largest share — especially when EF was <50%. Finerenone did not clearly reduce cause‑specific mortality
A mild-to-significant decline in left ventricular ejection fraction (LVEF) in heart failure with preserved ejection fraction (HFpEF) signals higher risks of lethal arrhythmias, sudden cardiac death, and mortality, underscoring the need for
Personalized increased pacing rates in patients with HFpEF and physiologic pacemakers may reduce adverse events and improve event-free survival, per a 4-year observational extension of the myPACE randomized trial.
Exercise-induced dynamic hyperinflation in HFpEF patients is linked to elevated pulmonary capillary wedge pressure, suggesting altered lung mechanics contribute significantly to exercise intolerance beyond ventricular stiffness alone.
This study reveals that excess adiposity, rather than insulin resistance or diabetes, predominantly drives left heart abnormalities and elevated pulmonary pressures in HFpEF, highlighting the need for targeted cardiometabolic therapies beyo
Tirzepatide reduces heart failure risk in obese HFpEF patients regardless of BMI or central adiposity, with greater benefits on exercise capacity and symptom scores associated with higher BMI and weight loss.
Empagliflozin alters peripheral microvascular responses in HFpEF patients, enhancing insulin-mediated vasodilation but reducing acetylcholine responsiveness, suggesting a targeted vascular mechanism distinct from general endothelial or smoo
A pooled analysis of four heart failure trials explores the relationship between obesity and kidney outcomes, revealing waist circumference and waist-to-height ratio as key risk factors, while body mass index showed no significant associati